Topoisomerase I-IN-20

Topoisomerase I-IN-20 (Compound 11d) (25-100 μM; 30 min) inhibits human topoisomerase I-mediated DNA relaxation^[1].
Topoisomerase I-IN-20 potently inhibits the proliferation of human A549 lung cancer cells with an IC₅₀ of 8.06 μM; it exhibits moderate activity against MCF-7, HepG-2 and SGC-7901 cells, and shows extremely low toxicity toward normal HK-2 cells^[1].
Topoisomerase I-IN-20 (0-10 μM; 0-48 h) inhibits migration of human lung adenocarcinoma cell line A549^[1].
Topoisomerase I-IN-20 (4-16 μM; 48 h) increases the intracellular ROS level in human lung cancer A549 cells in a dose-dependent manner^[1].
Topoisomerase I-IN-20 (4-16 μM; 24-48 h) induces S-phase cell cycle arrest and apoptosis in human lung cancer A549 cells^[1].
Topoisomerase I-IN-20 (4-16 μM; 24 h) induces DNA double-strand breaks in human lung cancer A549 cells in a dose-dependent manner (by enhancing γ-H2AX phosphorylation), and activates the mitochondria-mediated apoptotic pathway (by upregulating the expressions of p53, Bax, caspase-3 and caspase-9, while downregulating the expression of Bcl-2)^[1].
Topoisomerase I-IN-20 (1-10 μM; 48 h) induces DNA damage in human lung cancer A549 cells, with significant damage observed at concentrations of 5 and 10 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.